CERTIFICATE OF MAILING

The stereby certify that on February 21, 2001, this paper (along with any open referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage in an expelope addressed to: Commissioner of Patents and Trademarks, ashington, DC 20231.

37 C.F.R. § 1.8(a) | 37 C.F.R. § 1.10 | as "Express Mail Post Office to Addressee" Mailing Label No.

Joy Michaels | Type or print pame of person mailing paper)

PATENTDocket No. 350013-71

RECEIVED

FEB 2 8 2001 TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application Of:

Colin Watts

Serial Number: 09/646,950

Filing Date: December 8, 2000

Entitled: USE OF INHIBITORS OF

MAMMALIAN ASPARAGINYL ENDOPEPTIDASE FOR THERAPY OF AUTOIMMUNE DISEASE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached Form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed. References AF, AG, FI, GA, GB, GC, GD, GE and GF are herein disclosed for the first time. Applicant previously filed an Information Disclosure Statement listing all other enclosed documents as being "on order".

SERIAL No.: 09/646,950



DOCKET No. 350013-71

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), as an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this Supplemental Information Disclosure Statement shall not be construed as an admission against interest in any manner.

CONCLUDING REMARKS

It is respectfully requested that the examiner indicate consideration of the cited references by returning a copy of the attached form PTO-1449 with initials or other appropriate marks with the initial Office Action, and that the references be made of record as cited references in the application.

Respectfully submitted,

Date: February 21, 2001

Spyros J. Lazaris

Registration No. 45,981

OPPENHEIMER WOLFF & DONNELLY LLP

2029 Century Park East, 38th Floor Los Angeles, CA 90067-3024

Telephone: (310) 788-5000 Facsimile: (310) 788-5100 RECEIVED

TECH CENTER 1600/2900

FORM	PTO-	1449 (Modified)		Docket No.:	350013-71		Serial No.:	09/646,950
		ENTS AND PUB	ICATIONS	~×//			Oction 110	
FOR A	PPLIC	ANT'S INFORMA	TION	proprioarito.	Oomi Wat	.0		
		E STATEMENT						
				Filing Date:	•		Art Unit: 1	644
		UI	NITED STATE	S PATENT	DOCUMEN	TS		
*Exr's. Inits.	Ref.	Patent No.	Date	Name		Class	Sub Class	Filing Date (if applic- able)
	AA							
	AB							
	•		FOREIGN P	ATENT DO	CUMENTS			
Exr's. Init.	Ref	Document No.	Date	Country	Class	Sub	Trar Yes	nslation? No
	AC	WO 91/06571	16.05.91	PCT				
	AD	WO 94/24281	27.10.94	PCT				
	AE	WO 97/40066	30.10.97	PCT				
	AF	EP 0430645B1	27.11.90	EPO		Ī		
	AG	EP 0478602B1	20.06.90	EPO				
	ОТ	HER REFERENC	ES (Including	Author, Da	ate, Title, P	ertiner	nt Pages, Et	c.)
Exr's. Inits.	Ref.	Bibliographic D	ata		·			
	AH	Agrawal, Sudhi Pharmacokinet phosphorothioa	ics, biodistribu	ition, and sta	ability of olig	odeox	ynucleotide	*
	Al	Xiao, Bao-Guo Prevent and Tr IMMUNOPATH	eat Autoimmu	ne Diseases	; CLINICAL	. IMMU	NOLOGY A	
	AJ	Altmann, Danie Transgenic Mid Presence and 2 875	e to Human N	Nyelin Basic	Protein and	Other	Antigens in I	the
	AK	Fineschi, Beatr processing; EL					al proteases	and antigen
	AL	Agrawal, Sudh and phosphoro PROC.NATL.A	thioates as in	hibitors of hu	ıman immul	nodefic		midates
Examir	ner				Date Cons	idered		
* Evon	inor: li	nitial if citation cor	acidored who	ther or not of	totion is in (onform	anco with M	IDED (T

* Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. ¶ 609. Draw line through citation (i.e., eitation) if not in conformance and not considered include copy of this form with next communication to applicant.

All references PREVIOUSLY CONSIDERED. This paper is included to correct the publication Page softor citations BC (page 2) and EI (page 5)

FEB 2 8 2001

TECH CENTER 1600/2900

		449 (Modified) Serial No.: 09/646,950					
FOR A	PPLIC/	ENTS AND PUBLICATIONS poplicants: Colin Watts ANT'S INFORMATION E STATEMENT PATENTS					
		Filing Date: Sept. 25, 2000 Art Unit: 1644					
	ОТН	ER REFERENCES (Including Author, Date, Title, Pertinent Pages, Etc.)					
Exr's. Inits.	Ref.						
	ВА	Vinitsky, Alexander, et al.; 1994; Inhibition of the Proteolytic Activity of the Multicatalytic Proteinase Complex (Proteasome) by Substrate-Related Peptidyl Aldehydes; THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 269; pp. 29860-29866					
	ВВ	Agrawal, Sudhir and John Goodchild; 1987; Oligodeoxynucleoside Methylphosphonates; Synthesis and Enzymic Degradation; TETRAHEDRON LETTERS, Vol. 28, No. 32, pp. 3539-3542					
	ВС	Agrawal, Sudhir and JY. Tang; Efficient Synthesis of Oligoribonucleotide and its Phosphorothioatae Analogue Using H-Phosphonatae Approach; pp. 7541-7544; 199					
·	BD	Agrawal, Sudhir, et al.; February 1990; Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides; PROC. NATL. ACAD. SCI. USA, Vol. 87; pp. 1401-1405					
	BE	Altri, Enrica, et al.; October 1993; CGP 53437, an Orally Bioavailable Inhibotor of Human Immunodeficiency Virus Type 1 Protease with Potent Antiviral Activity; ANTIMICROBIAL AGENTS AND CHEMOTHERAPY; pp. 2087-2092					
	BF	Androlewicz, Matthew J. and Peter Cresswell; April 1994; Human transporters Associated with Antigen Processing Possess a Promiscuous Peptide-Binding Site; IMMUNITY, Vol 1; pp. 7-14					
	BG	Bannwarth, Willi; 1988; Solid-Phase Synthesis of Oligodeoxynucleotides Containing Phosphoramidate Internucleotide Linkages and their Specific Chemical Cleavage; HELVETICA CHIMICA ACTA, Vol. 71; pp. 1517-1527					
	BH	Benjamin, Christopher, W.; et al.;1998; Caspase Activation in MCF7 Cells Responding to Etoposide Treatment; MOLECULAR PHARMACOLOGY; pp. 446- 450					
· · · · · · · · · · · · · · · · · · ·	BI V	Brömme, Dieter and Hans-Ulrich Demuth; 1994; N,O-Diacyl Hydroxamates as Selective and Irreversible Inhibitors of Cysteine Proteinases; METHODS IN ENZYMOLOGY, Vol. 244; pp. 671-685					
· · · · · · · · · · · · · · · · · · ·	BJ	Buttle, David J.; 1994; Affinity Chromatography of Cysteine Peptidases; pp. 639-649					
	BK	Chen, Jinq-May, et al.; 1997; Cloning, Isolation, and Characterization of Mammalian Legumain, an Asparaginyl Endopeptidase; THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 272, No. 12; pp. 8090-8098					
Examin	er	Date Considered					
<u> </u>		Will the West Common and the Management of the Common and with M.D.C.D. St.					

^{*} Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. ¶ 609. Draw line through citation (i.e., citation) if not in conformance and not considered. Include copy of this form with next communication to applicant.

All references PREVIOUSLY CONSIDERED. This paper is included to correct the publication considered of a citations BC (page 2) and EI (page 5)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /PV/

FORM	PTO-1449 (Modified)	Docket No.: 350013-71	Serial No.: 09/646,950				
		Applicants: Colin Watts					
	PPLICANT'S INFORMATION DSURE STATEMENT (FB 200	E S					
		_(\$/	Art Unit: 1644				
	CENT & TRAD	EM.					
	OTHER REFERENCES (Includi	ng Author, Date, Title, Pertine	nt Pages, Etc.)				
Exr's. Inits.	Ref. Bibliographic Data						
		Chapman, Harold A.; 1998; Endosomal proteolysis and MHC class II function; CURRENT OPINION IMMUNOLOGY; pp. 93-102					
	caspases, clostripain and g FEBS Letters 441; pp. 361	ACMC 1996.1 Steam agreement over 1 decision, 1996. 1997. 1997.	ine and endopeptidases;				
		CC Cohen, Gerald, et al.; 1990; Microbial isopenicillin N synthase genes: structure, function, diversity and evolution; TIBTECH, Vol. 8; pp. 105-111					
	CD Cosstick, Richard and Joseph S. Vyle; 1989; Solid Phase Synthesis of Oligonucleotides Containing 3'-Thiothymidine; TETRAHEDRON LETTERS, Vo. 30, No. 35; pp. 4693-4696						
	CE Cresswell, Peter; February Function; CELL, Vol. 84; pp	1996; <i>Invariant Chain Structure</i> p. 505-507	and MHC Class II				
	CF Dalton, J.P., et al.; 1995; A mansoni; PARASITOLOGY	sparaginyl endopeptidase activi /; pp. 575-580	ty in adult Schistosoma				
	CG / Davidson, Howard W. and Specific Antigen by B Lymp pp, 85-92	Colin Watts; July 1989; <i>Epitope-</i> phocytes; THE JOURNAL OF CI	directed Processing of ELL BIOLOGY, Vol. 109;				
	Processing of Membrane Is in B Lymphocytes; THE JO	Processing of Membrane IgG and Monovalent Antigen/Membrane IgG Compleses in B Lymphocytes; THE JOURNAL OF IMMUNOLOGY, Vol. 144; pp. 4101-4109					
	Goodchild, John, et al.; Augreéplication by antisense oligy Vol. 85; pp. 5507-5511						
		Hewitt, Eric W., et al.; 1997; Natural Processing Sites for Human Cathespin E and Cathespin D in Tetanus Toxin; pp. 4693-4699					
s direction		<i>Oligonucleotide N-Alkylphospho</i> ; AMERICAN CHEMICAL SOCII					
	│	1993; The Two Cysteine Endopo aracterization by Use of Specific ISTRY AND BIOPHYSICS; pp. 2	: Fluorometric Assay;				
Examin	er	Date Considered					
609. D	iner: Initial if citation considered, wherewelline through citation (i.e., citation this form with next communication	n) if not in conformance and not	••				

All references PREVIOUSLY CONSIDERED. This paper is included to correct the publication dates for citations BC (page 2) and EI (page 5)

FEB 2.8 2001.

FORM PTC	9-1449 (Modified)	Docket No.:	350013-71	Seria 160.903/646,950			
FOR APPL	ATENTS AND PUBLICATIONS ICANT'S INFORMATION RE STATEMENT	Applicants:	Colin Watts	O TO WILL THE PARTY OF THE PART			
		Filing Date:	Sept. 25, 2000	Att Unit: 16			
				E INN			
	THER REFERENCES (Includin	g Author, Da	ate, Title, Pertinen	it Pages, Etc.)			
Inits.	Ref. Bibliographic Data						
D/	A √Kirschke, Heidrun, et al.; 1998; Lysosomal Cysteine Proteases, Second Edition						
DE	DB Krantz, Allen; 1994; Peptidyl (Acyloxy)methanes as Quiescent Affinity Labels for Cysteine Proteinases; pp. 656-671						
DC	DC Kudo, Jiro, et al.; November 1985; Structure of the human gene encoding the /invariant γ-chain of class II histocompatibility antigens; NUCLEIC ACIDS RÉSEARCH, Vol. 13, No. 24; pp. 8827-8841						
DE	DD Lanzavecchia, Antonio; 1985; Antigen-specific interaction between T and B cells; NATURE, Vol. 314, No. 5011; pp. 537-539						
DE	Leitér, Josef M.E., et al.; 1990; Inhibition of influenza virus replication by phosphorothioate oligodeoxynucleotides; PROC. NATL. ACAD. SCI. USA; pp. 3430-3434						
DF	DF /Lu, Jianyn and Herman van Halbeek; 1996; Complete H and C resonance assignments of a 21-amino acid glycopeptide prepared from human serum transferrin; CARBOHYDRATE RESEARCH; pp. 1-21						
DC							
DF	Makoff, Andrew J., et al.; October 1989; Expression of Tetanus Toxin fragment C in É. Coli: Is Purification and Potential Use as a Vaccine; BIO/TECHNOLOGY VOL. 7; pp. 1043-1046						
DI	Manoury, Bénédicte, et al.; 1998; An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation; NATURE, Vol. 396; pp. 695-699						
D	Mikáelian, Ivan and Alain Sergeant; 1992; A general and fast method to generate multiple site directed mutations; NUCLEIC ACIDS RESEARCH, Vol. 20, No. 2						
DH	Nielsen, John, et al.; 1988; Synthesis and Characterization of Dinucleoside Phosphorodithioates; TETRAHEDRON LETTERS, Vol. 29, pp. 2911-2914						
DL O'Sullivan, Deirdre M., et al.; 1986; Structure of the human la-a (γ)-chain gene: Identification of 5' sequences shared with major complex class II genes; PROC. NATL. ACAD. SCI. USA; pp. 44				ajor histocompatibility			
Examiner			Date Considered				
609. Draw	Initial if citation considered, who line through citation (i.e., citation form with next communication to	a) if not in con					
copy or triis	TOTAL WITH HEAT COMMUNICATION TO	o applicant.					

All references PREVIOUSLY CONSIDERED. This paper is included to correct the publication dates for citations BC (page 2) and EI (page 5)

RECEIVED

FEB 2 8 2001

FORM PTO-1449 (Modified)			Docket No.: 350013-71	Serial No.: 99/646,950				
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT			Applicants: Colin Watts	26 2011 E				
			Filing Date: Sept. 25, 2000	AN UNI: 1644				
		·		FIENT & TRADE				
	OTH	IER REFERENCES (Includin	g Author, Date, Title, Pertine	nt Pages, Etc.)				
Exr's.	Ref	Bibliographic Data						
Inits.								
	EA	Palmer, James T., et al.; 1995; Vinyl Sulfones as Mechanism-Based Cysteine						
	EB	Protease Inhibitors; J. MED.	CHEM., pp. 3193-3196					
	EC V	Pónd, Leslie and Colin Watts; 1997; Characterization of Transport of Newly Assembled, T Cell-Stimulatory MHC Class II-Peptide Complexes from MHC Class II Compartments in the Cell Surface; THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS; pp. 543-553						
	ED /	Riese, Richard J., et al.; 1996; Essential Role for Cathepsin S in MHC Class II- Associated Invariant Chain Processing and Peptide Loading; IMMUNITY, Vol. 4; pp. 357-366						
-	EE	Sharma, K. Krishna, et al.; 1996; <i>Identification of New Lens Protease(s) Using Peptide Substrates Having in Vivo Cleavage Sites</i> ; BIOCHEMICAL AND /BIOPHYSICAL RESEARCH COMMUNICATIONS; pp. 365-370						
	EF	Şhaw, Elliott; 1994; <u>Peptidyl Diazomethanes as Inhibitors of Cysteine and Serine</u> <u>Proteinases</u> ; METHODS IN ENZYMOLOGY; 649-656						
	EG	Shaw, Elliott and George D. J Green; 1981; Inactivation of Thiol Proteases with Peptidyl; METHODS IN ENZYMOLOGY; pp. 820-826						
	EH	Shaw, Jeng-Pyng, et al.: 1991; Modified deoxyoligonucleotides stable to /exonuclease degradation in serum; NUCLEIC ACIDS RESEARCH, Vol. 19; pp. 747-750						
	EIV	Thompson, Robert C.; Peptide Aldehydes: Potent Inhibitors of Serine and Cysteine Proteases; ENZYMES, ANTIBODIES AND OTHER PROTEINS; pp. 220-225; 1977						
	EJ Uznánski, Bogdan, et al.;1987; Deoxyribonucleoside 3'-Phosphordiamidite Substrates for Solid Supported Synthesis of Oligodeoxyribonucleotides and Phosphorothioate and DNA-Triester Analogues; 1987; TETRAHEDRON LIVol. 28; pp. 3401-3404							
	EK		1997; Degradation of Mouse In Influence of Major Histocompa)., Vol. 186; pp. 549-560					
Examin	er		Date Considered	1				
			ether or not citation is in conformation in conformation and not in conformance and not					

All references PREVIOUSLY CONSIDERED. This paper is included to correct the publication Page 5 of or citations BC (page 2) and EI (page 5)

copy of this form with next communication to applicant.

RECEIVED

FFR 9 8 2001

FORM PTO-1449 (Modified)			Docket No.: 350013-71	Serial No.P09/646,950				
LIST OF PATENTS AND PUBLICATIONS			Applicants: Colin Watts					
		ANT'S INFORMATION E STATEMENT		FB 26 2001 E				
DISCL	USUKI	ESTATEMENT	Filing Date: Sept. 25, 2000	Art U(3); 1644				
			т	TRADEMAN				
	OTH	HER REFERENCES (Includin	g Author, Date, Title, Pertine	ent Pages, Etc.)				
Exr's. Inits.	Ref							
·	FA	Watts, Colin; 1997; Capture Presentation on MHC Molec	and Processing of Exogenous ules; ANNU. REV. IMMUNOL.	Antigens for ; pp. 821-850				
	FB_{\bigvee}		neth G. Mann; 1993; <i>Peptide C</i> DS IN ENZYMOLOGY, Vol. 22					
	FC \checkmark	Restricted T Cell Responses 181	1994; Human Major Histocomp s in Transgenic Mice; J. EXP. N	MED. Vol. 180; pp. 173-				
	FD	Yamamoto, Ken, et al.; July 1994; Functional Interaction between Human Histocompatibility Leukocyte Antigen (HLA) Class II and Mouse CD4 Molecule in Antigen Recognition by T Cells in HLA-DR and DQ Transgenic Mice; J. EXP. MED., Vol. 180; pp. 165-171						
	FE	Cantorna, Margherita T., et al.; 1988; 1,25-Dihydroxycholecalciferol Inhibits the Progression of Arthritis in Murine Models of Human Arthritis; AMERICAN SOCIETY FOR NUTRITIONAL SCIENCES; pp. 68-72						
	FF /	Kumar, Vipin, et al.; May 1997; Regulatory T Cells Specific for the Same Framework 3 Region of the Vβ8.2 Chain Are Involved in the Control of Collagen II-induced Arthritis and Experimental Autoimmune Encephalomyelitis; J. EXP. MED., Vol. 185; pp. 1725-1733						
	FG	Sarin, Prem S., et al.; October 1988; Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates; PROC. NATL. ACAD. SCI. USA, Vol. 85; pp. 7448-7451 [incorrectly listed on original IDS as Vol. 86, pp. 7790-7794].						
	FH	Tang, Jin yan, et al.; 1993; Self-stabilized antisense oligodeoxynucleotide phosphorothioates: properties and anti-HIV activity; NUCLEIC ACIDS RESEARCH, Vol. 21; pp. 2729-2735						
	FI	Bogyo, Matthew and Hidde I Blood; NEWS AND VIEWS;	Ploegh; December 1998; <i>A i</i> pp. 625-627	Protease Draws First				
Examin	er		Date Considered	d .				
F =		itial if attacking annulational and		manage with MADED 4				
609. D	raw lin	•	ether or not citation is in confor a) if not in conformance and no applicant	••				

All references PREVIOUSLY CONSIDERED. This paper is included to correct the publication age of for citations BC (page 2) and EI (page 5)

RECEIVED

FEB 2 8 2001

FORM PTO-1449 (Modified)			Docket No.: 350013-71	Serial No.: 09/646,950		
FOR A	PPLIC	ENTS AND PUBLICATIONS ANT'S INFORMATION E STATEMENT	Applicants: Colin Watts	THE 28		
			Filing Date: Sept. 25, 2000	Art Unit: \$644		
	OTI	JED DECEDENCES (Includin	m Author Data Title Bortine	Total Tomas To		
OTHER REFERENCES (Including Author, Date, Title, Pertinent Pages, I						
Exr's. Inits.	Ref					
	GA	Knight, Andrew M.; et al.; 1997; Antigen endocytosis and presentation mediated by human membrane lgG1 in the absence of the lgα/lgβ dimer, THE EMBO JOURNAL, Vol. 16; pp. 3842-3850				
	GB	Makoff, A.J., et al.; 1989; Expression of tetanus toxin fragment C in E.coli: high level expression by removing rare codons; NUCLEIC ACIDS RESEARCH, Vol. 17; pp. 10191-10201				
	GC	Makoff, A.J. and M.D. Oxer; 1991; High level heterologous expression in E.coli using mutant forms of the lac promoter, NUCLEIC ACIDS RESEARCH, Vol. 19; pp. 2417-2421				
	GD	Simitsek, Phaedra D., et al.; June 1995; Modulation of Antigen Processing by Bound Antibodies Can Boost or Suppress Class II Major Histocompatibility Complex Presentation of Different T Cell Determinants; J. EXP. MED., Vol. 181; pp.1957-1963				
	GE	Strubin, Michel; et al.; 1984; The complete sequence of the mRNA for the HLA-DR-associated invariant chain reveals a polypeptide with an unusual transmembrane polarity; THE EMBO JOURNAL, Vol. 3; pp. 869-872				
	GF	Peptimmune and Peptide Therapeutics collaborate on asthma and autoimmune diseases; PHARMACEUTICAL BUSINESS NEWS, March 25, 1998				
	GG	를 보면 하는 것이 되었다. 이 이 사람들은 사람들은 사람들은 사람들은 사람들은 사람들은 사람들은 사람들은				
	GH	[[전상] 그리고 하는 경우를 가장했다면 함께 되는 경우를 하셨다면 하셨다면 하는 것이다.				
	GI	and a la comparta de la comparta de A encomparta de la comparta de la co				
in a line	GJ					
5 L.	GH					
	Examiner /F Pierre VanderVegt/		Date Considered			

^{*} Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. ¶ 609. Draw line through citation (i.e., citation) if not in conformance and not considered. Include copy of this form with next communication to applicant.

Page 7of 7

All references PREVIOUSLY CONSIDERED. This paper is included to correct the publication dates for citations BC (page 2) and EI (page 5)

RECEIVED

FFB 2 8 2001 TECH CENTER 1600/2900